The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
Interstitial lung disease (ILD), which is characterized by pulmonary fibrosis, is a diverse group of disorders. Nintedanib, an antifibrotic drug, is known to attenuate disease progression in ILD with progressive fibrosis, but its efficacy in autoimmune-disease-related ILD remains uncertain. We condu...
Saved in:
Main Authors: | Aulia Rahman Ardan (Author), Fariz Nurwidya (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
by: Woodcock HV, et al.
Published: (2013) -
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024) -
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
by: Bonella F, et al.
Published: (2015) -
The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024) -
Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
by: Alexandra Nagy, et al.
Published: (2021)